Leo Pharmas Delgocitinib triumphs in Phase III hand eczema trial
Leo Pharma can once again report positive news regarding the company’s JAK inhibitor delgocitinib, which in a Phase III study has managed to reach both the primary and secondary endpoints.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.